Ogilvie G K, Straw R C, Jameson V J, Walters L M, Lafferty M, Powers B E, Henkel S E, Withrow S J
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins 80523.
J Am Vet Med Assoc. 1993 Jun 1;202(11):1845-8.
We evaluated the development of nephrotoxicosis in 64 dogs with malignant neoplasia given cisplatin during 4-hour saline solution diuresis. Cisplatin (70 mg/m2 of body surface area, IV, q 21 d) was given to 8 dogs once, 22 dogs twice, 9 dogs 3 times, and 25 dogs 4 times. For each treatment, cisplatin was given over a 20-minute period after saline (0.9% NaCl) solution was administered IV for 3 hours at a rate of 25 ml/kg/h. After cisplatin infusion, saline solution diuresis was continued at the same rate for 1 hour. Before each treatment with cisplatin, the dogs were evaluated by conducting a physical examination, CBC; and analysis of serum urea nitrogen and creatinine concentrations, and in most cases, serum phosphorus concentration and urine specific gravity were determined. Exogenous creatinine clearance also was evaluated in 8 dogs prior to 1 (n = 8), 2 (n = 8), 3 (n = 6), and 4 (n = 4) treatments. Five (7.8%) of 64 dogs developed clinically evident renal disease after two (n = 3) and three (n = 2) doses of cisplatin. Two of the 5 dogs had preexisting diseases of the urinary tract prior to the start of treatment. Survival time in dogs that developed renal disease (median, 114 days; range, 26 to 273 days) was similar to that of all dogs in this study (median, 145 days; range, 5 to 586 days), with 30 dogs still alive at the conclusion of the study. Three of the 5 dogs that developed renal disease were alive at the conclusion of the study, 1 died of tumor-related causes, and another died as a direct result of nephrotoxicosis. There was a significant (P < 0.05) decrease in median neutrophil counts and a significant (P < 0.05) increase in median creatinine concentrations prior to the third and fourth treatments, compared with pretreatment values.(ABSTRACT TRUNCATED AT 250 WORDS)
我们评估了64只患有恶性肿瘤的犬在4小时生理盐水利尿期间接受顺铂治疗后肾毒性的发展情况。8只犬接受顺铂单次给药(70mg/m²体表面积,静脉注射,每21天一次),22只犬接受两次给药,9只犬接受三次给药,25只犬接受四次给药。每次治疗时,在以25ml/kg/h的速率静脉输注生理盐水(0.9%氯化钠)溶液3小时后,在20分钟内给予顺铂。顺铂输注后,以相同速率继续生理盐水利尿1小时。在每次顺铂治疗前,对犬进行体格检查、全血细胞计数,并分析血清尿素氮和肌酐浓度,在大多数情况下,还测定血清磷浓度和尿比重。在第1次(n = 8)、第2次(n = 8)、第3次(n = 6)和第4次(n = 4)治疗前,还对8只犬评估了外源性肌酐清除率。64只犬中有5只(7.8%)在接受两次(n = 3)和三次(n = 2)顺铂剂量后出现临床明显的肾脏疾病。这5只犬中有2只在治疗开始前就患有泌尿系统疾病。出现肾脏疾病的犬的生存时间(中位数为114天;范围为26至273天)与本研究中所有犬的生存时间(中位数为145天;范围为5至586天)相似,研究结束时仍有30只犬存活。出现肾脏疾病的5只犬中有3只在研究结束时存活,1只死于肿瘤相关原因,另1只直接死于肾毒性。与治疗前值相比,在第三次和第四次治疗前,中性粒细胞计数中位数显著降低(P < 0.),肌酐浓度中位数显著升高(P < 0.05)。(摘要截短至250字)